Document is current
Any future updates will be listed below
-
Authors
Ollonen, Teemu
Kurkela, Margareta
Laitakari, Anna
Sakko, Samuli
Koivisto, Henna
Myllyharju, Johanna
Tanila, Heikki
Serpi, Raisa
Koivunen, Peppi https://orcid.org/0000-0002-2827-8229
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (266719, 308009, 296498, 251314)
Academy of Finland (284605)
Sigrid Juséliuksen Säätiö
Jane ja Aatos Erkon Säätiö
Biocenter Finland
University of Oulu including Oulu University Hospital
- License Information
-
More Information
Article History
Received: 5 January 2022
Revised: 27 June 2022
Accepted: 29 June 2022
First Online: 19 July 2022
Declarations
:
: Financial interests: JMy owns equity in FibroGen, Inc., which develops HIF-P4H inhibitors as therapeutics and supports research in JMy laboratory. The other authors have no relevant financial or non-financial interests to disclose.
: All animal experiments were performed according to protocols approved by the Animal Experiment Board of Finland (ESAVI-8179-04.10.07-2017).
